By Josh BeckermanShares of molecular diagnostics company Biocept were down 46% following a Friday chapter 7 bankruptcy filing after the company considered strategic alternatives. The stock was at 55 cents on Monday and is down about 97% this year.

Source: Wall Street Journal October 17, 2023 02:16 UTC